


# Alzheimer's Association TrialMatch

Keith Fargo, PhD  
Director of Scientific Programs  
Alzheimer's Association

alzheimer's  association®

## How TrialMatch Works

- 1 A person with the dementia, caregiver, or healthy volunteer completes a **profile** via internet or phone.



trialmatch®

POWERED BY 

alzheimer's  association®

2

## How TrialMatch Works

- 2 Their unique profile is compared to structured match criteria, and the user is given a **customized list** of matching studies.



trialmatch®

POWERED BY  EmergingMed

alzheimer's  association®

3

## How TrialMatch Works

- 3 The user then selects the studies that are of most interest to **them**; results are **sorted** by study type and by distance from home



trialmatch®

POWERED BY  EmergingMed

alzheimer's  association®

4

## How TrialMatch Works

- 4 The user then **contacts the study team directly**, if they find a matching study that interests them.




trialmatch®









POWERED BY 

alzheimer's  association®

5

## User Experience



Title	Location	Contact	Bookmark
AZT-001: Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease	Schaumburg, IL 19 mi Change location		
An Efficacy and Safety Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)	Elk Grove Village, IL 20 mi Change location		
221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (ENGAGE)	Elk Grove Village, IL 20 mi Change location		
221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early	Elk Grove Village, IL 20 mi		


- Works on computers and mobile devices
- Phone agents available 8 am to 8 pm, M-F
- Studies are presented in order of proximity to nearest study site
- Studies organized into treatment, prevention, online, etc.
- Studies can be bookmarked for easy viewing later

alzheimer's  association®

6

**Study description**

Find and contact a trial site near you



Department of Neurology - Northwestern University, Feinberg School of Med  
 320 E. Superior  
 Chicago, IL  
 Site contact: Kristine Lipowski  
 Phone: 312-503-2486

[Call](#)

[View All Matched Studies](#)


**Study description**

Patient Summary | **Health Professional Summary**

**Short Title** Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)





**Purpose** This study is testing a new medication. This study asks: *Can a new medication slow down the development of thinking and memory problems associated with the onset of Alzheimer's? The study is designed to answer this question for people who may be at high risk for Alzheimer's, but who do not yet have Alzheimer's.* This study is looking for: Older men and women who are currently in good physical and mental health and have normal cognitive and memory function. Up to 1000 people in the USA, Canada, and Australia will participate.

**Eligibility** You could be eligible for this study if:  
 - You are between 65 and 85.

alzheimer's  association®

7

## Second Pass Matching

---

Dear George,


Thank you for being part of Alzheimer's Association TrialMatch®. Progress in Alzheimer's and dementia research depends on clinical studies — studies that need people like you in order to move forward.

Great news! A new study has opened near you. And based on the information in your profile, we believe it may be a good match.

**The A4 Study**

Can a new medication slow down the development of thinking and memory problems associated with the onset of Alzheimer's? The A4 study (Anti-Amyloid Treatment in Asymptomatic Alzheimer's) is designed to answer this question for people who may be at high risk for developing Alzheimer's but who do not yet have any signs of memory loss. If you are between the ages of 65 and 85 with normal thinking and memory function you may be a fit for the A4 study.

When a new study is added, an email is sent to existing TrialMatch users within 200 miles of site

alzheimer's  association®

8

## Study Sources Clinicaltrials.gov and User Submitted

alzheimer's association®  
trialmatch®  
powered by 

**TrialMatch Listing Request Form**  
Complete all sections of this form, then submit the completed form and any required supporting documentation to [alztrialmatch@emergingmed.com](mailto:alztrialmatch@emergingmed.com). If you have questions about the listing request process, please call 877.769.4821.

Date of submission:

<b>Section 1: Information about the requestor</b>	<b>Section 3: Study identification number</b>
Requestor's name: <input type="text"/>	Study name: <input type="text"/>
Telephone: <input type="text"/>	Official study title: <input type="text"/>
Email address: <input type="text"/>	Protocol ID number(s) (please include as many as you know): <input type="text"/>
Organization: <input type="text"/>	Name of study sponsor: <input type="text"/>

## 2016 Study and Site Numbers


**275** average number of studies listed on TrialMatch (377 total throughout year)

**675** average number of unique study sites


**1330** average number of study-site combinations



## Studies by Participant Type




## User and Study Ages



## Promoting Clinical Trial Participation



## TrialMatch User Growth



**220,000  
users**

## 2016 User Numbers

**55,987** new accounts created

**35,890 (~65%)** via postcards

**22,367 (~40%)** completed a profile and reviewed match results

**15,050** clicked to view at least on study summary (average of 3 each)

## 2016 Q3/Q4 Second Pass Matching Numbers

**39** second pass matching campaigns

**39,690** people

**26.3%** unique open rate

**37.1%** click through rate



## Challenges for the Future

- Engaging participants in preclinical/prodromal phase
- Increasing participation of diverse individuals

## Alzheimer's Association: Funding Prevention Trials



ALZHEIMER'S  
**PREVENTION**  
INITIATIVE

# Spanish Language Promotion

alzheimer's association® [Regresar a la página principal](#)

[En Español](#) [In English](#) [Español Home](#) | [Acercas De Nosotros](#) | [Contacto](#)

[Acerca de Alzheimer](#) | [Señales y Síntomas](#) | [Tratamiento](#) | [Cuidados](#) | [Recursos](#)

[Diagnóstico](#) | [Tratamientos](#) | [Estudios Clínicos](#)

## Estudios Clínicos

Tamaño [A](#) [A](#) [A](#) | [Imprimir](#) | [Compartir](#)



**Los estudios clínicos ayudan el progreso**

En los últimos 15 años, los científicos han hecho muchos avances en el entendimiento de cómo el Alzheimer afecta el cerebro. Muchos de estos recientes conocimientos indican nuevas estrategias prometedoras de tratamiento, prevención y diagnóstico.

Aunque muchas ideas sobre el tratamiento y la prevención del Alzheimer se forman en laboratorio, la etapa final de las pruebas de las ideas usualmente implica hacer estudios clínicos. Ningún tratamiento avanza a la etapa de hacer pruebas clínicas hasta que hay evidencia fuerte que indica que ese tratamiento será tan bueno como (o mejor que) las terapias actualmente disponibles.

En los estudios clínicos tempranos, la seguridad de un tratamiento es probada con un pequeño grupo de voluntarios. Estudios tardíos evalúan la eficacia del tratamiento al probarlo con miles de participantes. Cientos de científicos están explorando métodos potenciales para tratar y prevenir la enfermedad de Alzheimer al hacer docenas de estudios a través de los Estados Unidos.

**Más información**



[La Guía Interactiva del Cerebro](#)

---

[Encuentre su oficina local](#)

[¿Qué le Pasa al Abuelito?](#)

[Folleto-Voluntarios sanos \(4 pages\)](#)

[TrialMatch-Postal informativa \(2 pages\)](#)

# Spanish Language Promotion

**No solo espere una cura.  
Ayúdenos a encontrarla.**

Todos pueden ayudar a avanzar la investigación de la enfermedad de Alzheimer.



alzheimer's association®  
trialmatch®  
powered by EmergingMed

[alz.org/TrialMatch](http://alz.org/TrialMatch)



**Usted valora su salud.  
Nosotros también la valoramos.**

Necesitamos voluntarios sanos en la lucha contra el Alzheimer.



alzheimer's association®  
trialmatch®  
powered by EmergingMed

[alz.org/TrialMatch](http://alz.org/TrialMatch)

# FY2016 Growth of Diverse TrialMatch Users

**40%** year-over-year for all users

**59%** for racially/ethnically diverse users

- FY15: 1,425
- FY16: 2,272

## Alzheimer's Association Research Website



The screenshot shows the Alzheimer's Association Research Center website. The header includes the logo 'alz.org® | research center' and the tagline 'advancing alzheimer's research worldwide'. A navigation menu contains links for HOME, SCIENCE & PROGRESS, CLINICAL TRIALS, FUNDING & COLLABORATION, YOU CAN HELP, STAY CURRENT, and VIDEO AND RESOURCES. Below the navigation, there is a main content area with a featured article titled 'A future without Alzheimer's' and a sidebar with a section titled 'Discovering tomorrow's treatments'. The sidebar also includes a 'Learn more' link and a pagination indicator showing '1 2 3 4 5'.

[alz.org/research](http://alz.org/research)

THE END OF  
ALZHEIMER'S  
**STARTS**  
WITH YOU

alzheimer's  association®  
alz.org

## February 3, 2017 -- Advisory Council Meeting #23

The meeting was held on Friday, February 3, 2017, in Washington, DC. The theme of this Advisory Council meeting was clinical trials for Alzheimer's disease and related dementias and recruitment challenges. Additional afternoon presentations included updates on progress towards a Care and Services Summit, federal workgroup updates, and preparation for the Advisory Council's 2017 Recommendations, due in April 2017. Material available from this meeting is listed below and is also available at <https://aspe.hhs.gov/advisory-council-alzheimers-research-care-and-services-meetings#Feb2017>.

Comments and questions, or alerts to broken links, should be sent to [napa@hhs.gov](mailto:napa@hhs.gov).

---

### General Information

<b>Agenda</b>	<a href="#">[HTML Version]</a> <a href="#">[PDF Version]</a>
<b>Meeting Announcement</b>	<a href="#">[HTML Version]</a> <a href="#">[PDF Version]</a>
<b>Meeting Summary</b>	<a href="#">[HTML Version]</a> <a href="#">[PDF Version]</a>
<b>Public Comments</b>	<a href="#">[HTML Version]</a>

### Handouts

<b>Panelist Bios</b>	<a href="#">[HTML Version]</a> <a href="#">[PDF Version]</a>
----------------------	--

### Presentation Slides

<b>2017 Recommendations</b>	<a href="#">[HTML Version]</a> <a href="#">[PDF Version]</a>
<b>Alzheimer's Association TrialMatch</b>	<a href="#">[HTML Version]</a> <a href="#">[PDF Version]</a>
<b>Clinical Services Subcommittee Federal Update</b>	<a href="#">[HTML Version]</a> <a href="#">[PDF Version]</a>
<b>Clinical Studies Recruitment Strategy</b>	<a href="#">[HTML Version]</a> <a href="#">[PDF Version]</a>
<b>Development and Use of Registries to Accelerate Enrollment into Alzheimer's Trials</b>	<a href="#">[HTML Version]</a> <a href="#">[PDF Version]</a>
<b>Long-Term Services and Supports Committee Update</b>	<a href="#">[HTML Version]</a> <a href="#">[PDF Version]</a>
<b>National Recruitment Strategy</b>	<a href="#">[HTML Version]</a> <a href="#">[PDF Version]</a>



<b>NINDS Update</b>	<a href="#">[HTML Version]</a> <a href="#">[PDF Version]</a>
<b>Randomized Controlled Trials for Alzheimer's Disease</b>	<a href="#">[HTML Version]</a> <a href="#">[PDF Version]</a>
<b>Strategies to Facilitate Recruitment and Screening for Alzheimer's Clinical Trials</b>	<a href="#">[HTML Version]</a> <a href="#">[PDF Version]</a>
<b>Transforming AD Therapy Development</b>	<a href="#">[HTML Version]</a> <a href="#">[PDF Version]</a>
<b>Update National Research Summit on Care, Services and Supports for Persons with Dementia and Their Caregivers</b>	<a href="#">[HTML Version]</a> <a href="#">[PDF Version]</a>

## **Videos**

<b>Welcome thru Perspectives</b>	<a href="#">[Video]</a>
<b>Rachel, Jessica, George Presentations</b>	<a href="#">[Video]</a>
<b>Keith Presentation and Panel Discussion</b>	<a href="#">[Video]</a>
<b>Public Comments</b>	<a href="#">[Video]</a>
<b>Care Summit and Milestones</b>	<a href="#">[Video]</a>
<b>Federal Workgroups and Adjourn</b>	<a href="#">[Video]</a>

---

Last Updated: 06/29/2018